These might be mainly attributed to the continuous development of immunotherapy and targeted therapy, for example tyrosine kinase inhibitors for kidney cancer [22], inhibitor of fibroblast growth factor receptor (FGFR) for bladder cancer [23] and targeted therapy for prostate-specific membrane antigen (PSMA) for prostate cancer [24]. This evidence concerns the gene FOLH1 and urinary bladder carcinoma.